A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas

D. J. Palmer, Morton F Goldberg, M. Frenkel, R. Fiscella, R. J. Anderson

Research output: Contribution to journalArticle

Abstract

Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar®). Twenty-six took an oral dosage of 50 mg/kg ('half-dose') every four hours for five days, up to a maximum of 30 g/day, and 33 patients received 100 mg/kg ('full-dose') every four hours up to a maximum of 30 g/day. Five patients in the full-dose group experienced dizziness, hypotension, and syncope. Half-dose Amicar® substantially reduced such serious side effects (P=0.063), had no adverse effect on the reduced rate of recurrent hemorrhages (P=0.22), and was more cost effective than the full-dose regimen. When the two patients in the half-dose group receiving 30 g/day of Amicar® were deleted, however, the comparison of dizziness and hypotension in the two groups became more significant (P=0.050). The incidence of nausea and vomiting was approximately the same in both groups (P=0.52). Serum Amicar® levels were within the range of plasminogen inhibition at both dose levels. Prior aspirin ingestion appeared to have no influence on the rate of rebleeding (P=0.58).

Original languageEnglish (US)
Pages (from-to)102-108
Number of pages7
JournalOphthalmology
Volume93
Issue number1
StatePublished - 1986
Externally publishedYes

Fingerprint

Hyphema
Aminocaproic Acid
Secondary Prevention
Dizziness
Hypotension
Plasminogen
Syncope
Nausea
Aspirin
Vomiting
Eating
Hemorrhage
Costs and Cost Analysis
Incidence
Wounds and Injuries
Serum

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas. / Palmer, D. J.; Goldberg, Morton F; Frenkel, M.; Fiscella, R.; Anderson, R. J.

In: Ophthalmology, Vol. 93, No. 1, 1986, p. 102-108.

Research output: Contribution to journalArticle

@article{bf41da8ec64b43a3b5acb9ab7fd550e6,
title = "A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas",
abstract = "Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar{\circledR}). Twenty-six took an oral dosage of 50 mg/kg ('half-dose') every four hours for five days, up to a maximum of 30 g/day, and 33 patients received 100 mg/kg ('full-dose') every four hours up to a maximum of 30 g/day. Five patients in the full-dose group experienced dizziness, hypotension, and syncope. Half-dose Amicar{\circledR} substantially reduced such serious side effects (P=0.063), had no adverse effect on the reduced rate of recurrent hemorrhages (P=0.22), and was more cost effective than the full-dose regimen. When the two patients in the half-dose group receiving 30 g/day of Amicar{\circledR} were deleted, however, the comparison of dizziness and hypotension in the two groups became more significant (P=0.050). The incidence of nausea and vomiting was approximately the same in both groups (P=0.52). Serum Amicar{\circledR} levels were within the range of plasminogen inhibition at both dose levels. Prior aspirin ingestion appeared to have no influence on the rate of rebleeding (P=0.58).",
author = "Palmer, {D. J.} and Goldberg, {Morton F} and M. Frenkel and R. Fiscella and Anderson, {R. J.}",
year = "1986",
language = "English (US)",
volume = "93",
pages = "102--108",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A comparison of two dose regimens of epsilon aminocaproic acid in the prevention and management of secondary traumatic hyphemas

AU - Palmer, D. J.

AU - Goldberg, Morton F

AU - Frenkel, M.

AU - Fiscella, R.

AU - Anderson, R. J.

PY - 1986

Y1 - 1986

N2 - Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar®). Twenty-six took an oral dosage of 50 mg/kg ('half-dose') every four hours for five days, up to a maximum of 30 g/day, and 33 patients received 100 mg/kg ('full-dose') every four hours up to a maximum of 30 g/day. Five patients in the full-dose group experienced dizziness, hypotension, and syncope. Half-dose Amicar® substantially reduced such serious side effects (P=0.063), had no adverse effect on the reduced rate of recurrent hemorrhages (P=0.22), and was more cost effective than the full-dose regimen. When the two patients in the half-dose group receiving 30 g/day of Amicar® were deleted, however, the comparison of dizziness and hypotension in the two groups became more significant (P=0.050). The incidence of nausea and vomiting was approximately the same in both groups (P=0.52). Serum Amicar® levels were within the range of plasminogen inhibition at both dose levels. Prior aspirin ingestion appeared to have no influence on the rate of rebleeding (P=0.58).

AB - Fifty-nine patients who sustained hyphema following blunt trauma were randomly assigned prospectively to either of two dose regimens of epsilon aminocaproic acid (Amicar®). Twenty-six took an oral dosage of 50 mg/kg ('half-dose') every four hours for five days, up to a maximum of 30 g/day, and 33 patients received 100 mg/kg ('full-dose') every four hours up to a maximum of 30 g/day. Five patients in the full-dose group experienced dizziness, hypotension, and syncope. Half-dose Amicar® substantially reduced such serious side effects (P=0.063), had no adverse effect on the reduced rate of recurrent hemorrhages (P=0.22), and was more cost effective than the full-dose regimen. When the two patients in the half-dose group receiving 30 g/day of Amicar® were deleted, however, the comparison of dizziness and hypotension in the two groups became more significant (P=0.050). The incidence of nausea and vomiting was approximately the same in both groups (P=0.52). Serum Amicar® levels were within the range of plasminogen inhibition at both dose levels. Prior aspirin ingestion appeared to have no influence on the rate of rebleeding (P=0.58).

UR - http://www.scopus.com/inward/record.url?scp=0022580814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022580814&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 102

EP - 108

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 1

ER -